This platform was employed to assess kinome adaptations to kinase inhibitors in multiple cancer models, including triple-negative breast cancer treated with MEK inhibitor selumetinib [9] and HER2-positive breast cancer treated with HER2 inhibitor lapatinib [10]. Here, ERBB2 is linked to breast carcinoma.